EHA

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) has managed to keep sell-side analysts encouraged with its last Friday's presentation at the European Hematology Association meeting. The latest sell-side firm to express its happiness over the data was Raymond James. Analyst Reni Benjamin termed the...

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) was at its volatile best all this week. After a 14-percent gain Monday, the stock pulled back slightly Tuesday and retreated by less than 2 percent Wednesday. It rallied over 10 percent Thursday, only to slip by about 7 percent Friday amid the Bellicum...

Barclays has raised the price target of Acceleron Pharma Inc (NASDAQ: XLRN) shares to $42 (18.5 percent upside) from $40, based on a recent data showing luspatercept's durability of response in MDS. Myelodysplastic Syndromes (MDS) is a condition where the bone marrow does not produce enough healthy...